BACE1 and Alzheimer disease: However, BACE1 inhibitors tested to date in clinical trials have yielded no benefit first in patients with mild-to-moderate AD and more recently in early or prodromal AD populations (Imbimbo and Watling, 2019; McDade et al., 2021; Bazzari and Bazzari, 2022).